NEW YORK, July 25, 2017 /PRNewswire/ -- Spherix Incorporated (“Spherix” or the “Company”) (NASDAQ: SPEX), an intellectual property development company committed to the fostering of technology, today announced the formation of a Technology Advisory Board in the area of biopharmaceutical opportunities.
The Technology Advisory Board was formed to assist the Company in evaluating potential opportunities in the biopharmaceutical arena, as well as to advise the Company in its work with Hoth Therapeutics. As previously reported, the Company recently acquired a controlling interest in Hoth Therapeutics, a company involved in the development of a novel topical treatment for patients suffering from atopic dermatitis, such as eczema. Individuals serving on the advisory board will provide the Company advice, support and technical assistance in reviewing diversification opportunities. The Company will announce the members and their respective credentials as they join.
Anthony Hayes, the Chief Executive Officer of Spherix stated, “As we continue to diversify and build the intrinsic value of Spherix, we believe the advisory board will provide valuable insights to the Company and its prospects. We are excited about our future growth potential.”
About Spherix Incorporated
Spherix Incorporated was launched in 1967 as a scientific research company. Spherix is committed to advancing innovation by participation in the development of new technology. Spherix draws on portfolios of pioneering technology to support product innovation.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. We are a small company with limited financial resources and our scientific background and abilities to implement a commercialization strategy is subject to ever-changing market conditions and rapidly-advancing technologies over which we have no control. While we believe that these forward-looking statements are reasonable, market conditions and competition in the marketplace is ever-changing and we have no control over these influences. As a result, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”) including, but not limited to, the Risk Factors relating to the Company’s patent business and other aspects of the Company’s business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Investor Relations Contact:
Hayden IR, LLC
Brett Mass
Phone: (646) 536-7331
Email: investorrelations@spherix.com
www.haydenir.com
Spherix Contact:
Phone: (703) 992-9325
Email: info@spherix.com
www.spherix.com
View original content with multimedia:http://www.prnewswire.com/news-releases/spherix-announces-the-formation-of-a-technology-advisory-board-in-area-of-biopharmaceutical-opportunities-300493421.html
SOURCE Spherix Incorporated
